Is CYCC a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

884 people get CYCC articles and Market Currents by email alert.

Get email alerts on CYCC »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Is It Now Time To Consider Cyclacel Pharmaceuticals?
Kevin Quon • Mon, May 27 • 7 Comments
A Bullish Argument For Cyclacel's Sapacitabine And Seamless
Brian Thomson • Thu, Apr 25 • 4 Comments
Cyclacel Settles With Celgene, Sacrifices Small Gains For Bigger Interests
Veziris Ventures • Thu, Apr 4 • 8 Comments
Cyclacel Pharma: Undervalued With Its Potential Blockbuster Drug
Scott Matusow • Thu, Feb 21 • 3 Comments
Celgene Corporation Vs. Cyclacel Pharmaceuticals, Inc.: The Markman Hearing And Its Likely Outcome
Veziris Ventures • Thu, Feb 14 • 8 Comments
Cyclacel Explained: Answers About The Long Misunderstood And Undervalued Biotech
Veziris Ventures • Thu, Jan 24 • 10 Comments
Upcoming AML Treatments - Which Company Will Fly?
Steve Rosenman • Mon, Dec 3, 2012 • 16 Comments
Cyclacel Heats Up On Clinical Trial Progression
Brian L. Wilson • Tue, Oct 16, 2012
Cyclacel: An Intriguing Long Shot
Stephen Simpson • Tue, Mar 20, 2012 • 7 Comments
Cyclacel Pharmaceuticals: A Little Left on the Upside
Kinetic Investments • Mon, May 16, 2011 • 1 Comment
The Catalysts That Will Propel Cyclacel Pharmaceuticals Higher
Jeremy Richards • Mon, Sep 20, 2010 • 13 Comments
Cyclacel Pharmaceuticals CEO Speaks About His Company
The Wall Street Transcript • Tue, Sep 25, 2007 • 1 Comment

To learn more about Seeking Alpha Pro, click here.

Non-Operating Income Hidden In Operating Earnings
David Trainer • Tue, Jun 18
Upcoming Catalysts For These BioPharmas Provide Potential Upside
Scott Matusow • Wed, Feb 20 • 20 Comments
Looking Beyond The JPM Global Healthcare Conference: More Biotech Than Meets The Eye
Nouvelle Asset Management • Tue, Jan 8 • 14 Comments
Biotech Weekly Recap: The Market Holds While Biotech Crumbles
Brian L. Wilson • Sun, Dec 9, 2012 • 6 Comments
3 Small-Cap Biopharmas With Trade Catalysts And Speculation Investment Potential
Scott Matusow • Tue, Dec 4, 2012 • 21 Comments
What Is So Exciting About MEI Pharma?
C.R. Jackson • Fri, Nov 16, 2012 • 3 Comments
Possible Reverse Split Should Be The Catalyst Needed To Take NeoStem Shares Higher
Amy Baldwin • Tue, Oct 23, 2012 • 33 Comments
Biotech Weekend Recap: Bears, Bears Everywhere
Brian L. Wilson • Mon, Oct 22, 2012 • 15 Comments
2.4% Yield And 10+ Potential Blockbuster Drugs
The Wall Street Transcript • Wed, Sep 26, 2012 • 15 Comments
4 Cash Loaded Biotech Stocks With Little Debt
ZetaKap • Thu, Aug 30, 2012 • 4 Comments
5 Pharmaceutical Companies With Phase III Clinical Study Catalysts This Year - Part IV
Markus Aarnio • Mon, Aug 20, 2012 • 6 Comments
Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 3
StockPandit • Fri, May 25, 2012 • 1 Comment
ArQule Dips, But Not Necessarily A Bargain
Stephen Simpson • Tue, Apr 10, 2012 • 2 Comments
Q3 Micro-Cap Biotech Picks By The World's Largest Fund Managers
GuruFundPicks • Thu, Dec 8, 2011 • 5 Comments
Top Fund Managers' Small Cap Biotech Picks
GuruFundPicks • Fri, Oct 14, 2011 • 14 Comments
8 Speculative Biotech Buys Based On Last Quarter's Biggest Movers
GuruFundPicks • Mon, Oct 3, 2011 • 2 Comments
Buy And Sell Ideas Based On Wednesday's Big News And Price Decliners
GuruFundPicks • Thu, Sep 29, 2011 • 1 Comment
Profit From These 3 Analysts' Stock Picks for Under $10
Simon Monger • Wed, Jul 13, 2011 • 1 Comment
7 Under the Radar Stocks That Tumbled on Friday and Why
Alex Shadunsky • Mon, Jul 4, 2011
3 Small Cap Biotechs Primed For Corrections
TheMarketFinancial • Mon, May 16, 2011 • 4 Comments

Cyclacel Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Mon, May 13
Cyclacel Pharmaceuticals Management Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Mar 27
Cyclacel Pharmaceuticals' CEO Presents at Lazard Capital Markets 9th Annual Healthcare Conference (Transcript)
Tue, Nov 13, 2012 • 2 Comments
Cyclacel Pharmaceuticals' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Mon, Nov 12, 2012
Cyclacel Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Aug 14, 2012

Cyclacel Pharmaceuticals Announces Closing of Underwritten Offering

GlobeNewswire (May 21, 2013)
Cyclacel Pharmaceuticals Announces $20 Million Underwritten Offering

GlobeNewswire (May 16, 2013)
Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock

GlobeNewswire (May 15, 2013)
Cyclacel Reports First Quarter 2013 Financial Results

GlobeNewswire (May 13, 2013)
Cyclacel Pharmaceuticals to Announce Release of First Quarter 2013 Financial Results

GlobeNewswire (May 10, 2013)
Cyclacel Reports Updated Phase 2 Survival Data of Sapacitabine for MDS

GlobeNewswire (Apr 30, 2013)
Cyclacel Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference

GlobeNewswire (Apr 23, 2013)
Combination Potential of Cyclacel's Sapacitabine and Seliciclib Reported at AACR

GlobeNewswire (Apr 9, 2013)
AACR Press Conference Highlights Combination Potential of Two Cyclacel Drugs

GlobeNewswire (Apr 8, 2013)
Cyclacel Announces Sale of Four Cyclacel Romidepsin-Related Patents to Celgene and Dismissal of All Claims in Their Patent Litigation

GlobeNewswire (Apr 4, 2013)
Cyclacel Announces Multiple Abstracts Selected for Presentation at American Association for Cancer Research Annual Meeting

GlobeNewswire (Apr 3, 2013)
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results

GlobeNewswire (Mar 27, 2013)
Cyclacel to Announce Year-End and Fourth Quarter 2012 Financial Results

GlobeNewswire (Mar 22, 2013)
Cyclacel Announces Grants of New U.S. & European Patents Covering Sapacitabine Used in Combination With HDAC Inhibitors

GlobeNewswire (Feb 12, 2013)
Cyclacel Pharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference

GlobeNewswire (Feb 4, 2013)
Cyclacel Reviews 2012 Achievements and Announces Key Business Objectives for 2013

GlobeNewswire (Jan 7, 2013)
Cyclacel Enters Into a $20 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC

GlobeNewswire (Dec 17, 2012)
Cyclacel Presents Updated Survival Data From the Pilot Study and Lead-In Phase of Seamless Phase 3 Study at the 2012 ASH Annual Meeting

GlobeNewswire (Dec 10, 2012)
Cyclacel to Report New Sapacitabine Clinical Data at the American Society of Hematology Annual Meeting

GlobeNewswire (Dec 4, 2012)
Cyclacel Reports Third Quarter 2012 Financial Results

GlobeNewswire (Nov 12, 2012)

CYCC vs. ETF Alternatives

Company Description

Cyclacel Pharmaceuticals, Inc. was incorporated in the state of Delaware in 1996 and is headquartered in Berkeley Heights, New Jersey with a research facility located in Dundee, Scotland. Cyclacel is a development-stage biopharmaceutical company dedicated to the discovery, development and... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, May 21, 7:38 PM Cyclacel Pharmaceuticals (CYCC) closes its previously announced underwritten offering totaling 6,833,334 shares at $3 per share for gross proceeds of approximately $20.5M. Shares +1% AH. Comment! [Healthcare]
Thursday, May 16, 12:51 PM Midday top 10 gainers: EGLE +46%. NBG +24%. SBSA +23%. DQ +22%. GNK +19%. AEGR +19%. GLBS +17%. SINO +17%. PRGN +16%. LWAY +16%.
Midday top 10 losers: NCT -54%. SNFCA -22%. ONTY -21%. INFI -19%. CNIT -15%. CYCC -14%. PTSX -14%. AMD -13%. BDCO -11%. TRIT -11%. 2 Comments [On the Move]
Thursday, May 16, 11:00 AM Shares of Cyclacel Pharmaceuticals (CYCC -13.5%) take a hit after it prices its previously announced public offering of 6.7 million shares at $3.00 each, a sharp 13% discount to its previous session close of $3.47. All of the shares are being sold by CYCC, and the proceeds will be used primarily to complete Phase 3 trials of its lead drug candidate, sapacitabine. Comment! [Healthcare, On the Move]
Thursday, May 16, 9:14 AM Premarket gainers: RGDX +24%. EGLE +23%. EFUT +19%. TSLA +13%. CSCO +13%. SCTY +11%. DQ +9%. HALO +8%. DANG +7%. AV +7%. YRCW +8%. NBG +7%. KSS +7%. SPWR +6%.
Losers: NCT -53%. SNFCA -24%. AMD -10%. NQ -7%. CYCC -5%. Comment! [On the Move]
Wednesday, May 15, 5:21 PM Cyclacel Pharmaceuticals (CYCC) announces an offering to sell shares, however the size and terms were not disclosed. The company also expects to grant the underwriters a 30-day option to cover overallotments, if any. All of the shares in this offering are to be sold by the company. JMP Securities LLC is acting as the sole book-running manager. Shares -7.5% AH. Comment! [Healthcare, On the Move]
Thursday, April 4, 9:51 AM Cyclacel (CYCC -2.8%) sells four patents to Celgene (CELG +0.8%) for a onetime payment of $5.5M, effectively resolving pending litigation between the two companies. Cyclacel is now free to get back to focusing "on the development of [its] pipeline," CEO Spiro Rombotis says. Comment! [Healthcare]
Wednesday, March 27, 4:33 PM Cyclacel Pharmaceuticals (CYCC): Q4 EPS of -$0.59. Shares +5.4% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
Tuesday, February 12, 12:42 PM Cyclacel Pharmaceuticals (CYCC +1%) says it's received patents in the U.S. and Europe for a combination treatment of sapacitabine, the company's lead product candidate, with HDAC inhibitors. The patents provide exclusivity until June 2029 and December 2027 respectively. Comment! [Healthcare, On the Move]
Monday, December 17, 2012, 11:22 AM Cyclacel Pharmaceuticals (CYCC -1%) says it's entered into a common stock purchase agreement with Aspire Capital Fund to help fund Phase III clinical trials for its leukemia drug sapacitabine. Under the terms of the agreement, Aspire will purchase up to $20M of CYCC's common stock from time to time over the next two years as directed by CYCC. Aspire already invested its first $1M in CYCC common stock at $6.29 on December 13th, immediately after executing the purchase agreement. 1 Comment [Healthcare]
Monday, December 10, 2012, 12:26 PM Shares of Cyclacel Pharmaceutical (CYCC -3.9%) slide after releasing updated survival data over the weekend from its Phase III studies of its oral sapacitabine capsules, a treatement for elderly patients with newly diagnosed acute myeloid leukemia who are not candidates for chemotherapy. The data was presented at the 54th Annual Meeting of the American Society of Hematology in Atlanta. Comment! [Healthcare, On the Move]
Wednesday, December 5, 2012, 12:45 PM Midday top 10 gainers: MMR +82%. EBOD +69%. MBLX +32%. PXP +26%. UEPS +25%. MITK +23%. AVAV +16%. CYCC +15%. CIE +15%. PLAB +13%.
Midday top 10 Losers: CHTP -36%. LORL -35%. TIBX -21%. MFRM -21%. ANIK -20%. SINO -19%. BLIN -18%. P -17%. THQI -17%. FIZZ -15%. 1 Comment [On the Move]
Tuesday, December 4, 2012, 1:44 PM Cyclacel Pharmaceuticals (CYCC +17.3%) pops today after announcing earlier that it will present analysis of Phase III testing of its leukemia drug candidates Sapacitabine and Decitabine. The testing was administered in alternating cycles in elderly patients with newly diagnosed acute myeloid leukemia at American Society of Hemoatology convention in Atlanta this weekend. Comment! [Healthcare, On the Move]
Tuesday, December 4, 2012, 12:45 PM Midday top 10 gainers: ALDA +54%. SINO +29%. CYCC +17%. LTBR +12%. CORT +12%. SAB +11%. EDMC +10%. CPGI +11%. PRIS +10%. ACLS +10%.
Midday top 10 Losers: UEPS -56%. GERN -24%. EXA -22%. CUR -20%. SSN -19%. PPHM -16%. IQNT -18%. PBY -14%. GURE -12%. LEDS -12%. 3 Comments [On the Move]
Monday, December 3, 2012, 12:45 PM Midday top 10 gainers: SQNS +32%. CLNT +26%. THTI +24%. RCON +16%. SGOC +15%. CYCC +14%. LTBR +13%. AXR +13%. ZAZA +13%. LPH +12%.
Midday top 10 Losers: TSRI -32%. AOL -14%. SEM -12%. GMED -10%. BCRX -10%. IMRS -9%. SARA -9%. DCTH -9%. DAIO -9%. RATE -9%. Comment! [On the Move]
Wednesday, October 24, 2012, 12:45 PM Midday top 10 gainers: SEH +61%. KIPS +25%. CHC +21%. FB +21%. LL +15%. PLCM +14%. ASPS +11%. DHX +12%. MNST +13%. CYCC +12%. Top 10 Losers: TPX -22%. IRBT -19%. CPWR -16%. UIS -15%. NFLX -14%. DSCO -14%. UTHR -13%. BWLD -12%. NSM -12%. NFX -12%. Comment! [On the Move]
Monday, October 15, 2012, 12:45 PM Midday top 10 gainers: CYCC +40%. BCOM +35%. IGLD +24%. YONG +16%. EQS +15%. DYAX +14%. ALN +13%. BSDM +11%. CLWR +11%. ESYS +9%.
Top 10 Losers: DCTH -19%. PRWT -17%. DHRM -10%. AMED -9%. PLXT -9%. GROW -8%. IMOS -8%. HAUP -7%. ILMN -7%. DAC -7%. Comment! [On the Move]

SynergyTrader
$CYCC - our software opened a position this morning @ 3.50 on the recent insider buying. Looking for 10% or 3.85 on this #trade
May 28, 12:38 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
Fuinhaz Setups for March 18 2013 | $AMZN $ARMH $CYCC $DRYS $GLUU $ONNN $PTRY $VOD http://bit.ly/ZMTYzv
Mar 18, 9:09 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
Trade call success on $TSRX Just printed a $6 needed this one after $CYCC not so well -- yet
Mar 5, 3:28 PM
Reply (8)

• !Report Abuse
View all 8 replies
u681694: Do you still think CYCC has long term potential as per your article ?
Mar 6, 3:06 PM
• !Report Abuse
StockMatusow: yes i do. but speculation wise. what if what goes down? what if a crazy man pisses on my lawn tomorrow?
Mar 6, 6:49 PM
• !Report Abuse
Add a reply...

140 characters

The Scientist
$ONCY potential is huge. Reolysin can also be used for many other cancer types. Following: $CYCC $CYTK $ONCY $SNTA $SRPT $YMI
12/13/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
Trade Alert: $CYCC Short Term Price Target Opion $6.10
12/3/12
Reply (23)

• !Report Abuse
View all 23 replies
amitschele: Well DANDISIK just when things start to look up we get another day in the trenches with ATRS.
12/13/12
• !Report Abuse
DANDISIK: @ amitschele $ATRS is becoming the ultimate either 1.) Tease Or 2.) Heartbreaker. Everyone needs to decide which one.
12/13/12
• !Report Abuse
Add a reply...

140 characters

ZetaKap
4 Cash Loaded Biotech Stocks With Little Debt http://bit.ly/NYQlHb $CYCC $OMPI $SSRX $VNDA @ZetaKap
8/30/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Scientist
Market cap CYCC $28M, VSTM $215M. VSTM with NO drugs in clinical trials. Zero. CYCC better hire the PR firm from VSTM
6/20/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Scientist
CYCC came out with great data on sapacitabine for MDS. Not only does it work well, but it also an ORAL med. Wall St ignoring good data again
6/1/12
Reply (1)

• !Report Abuse
View all 1 replies
John Rayhall: Looks like they are listening today. Too late to buy some?
10/15/12
• !Report Abuse
Add a reply...

140 characters

The Scientist
CYCC recently trading at cash. Wall St saying their drugs are worth $0! Both lead drugs sapacitabine and seliciclib show activity.
5/21/12
Reply (1)

• !Report Abuse
View all 1 replies
The Scientist: Sapacitabine in P3 studies headed by chair of leukemia at MD Anderson. Valuation does not make sense.
5/21/12
• !Report Abuse
Add a reply...

140 characters

The Scientist
CYCC is one of the most undervalued oncology stocks given its advanced pipeline. Data for lead drug sapacitabine looks very good.
4/11/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Scott Matusow
Trade call success on $TSRX Just printed a $6 needed this one after $CYCC not so well -- yet
Mar 5, 3:28 PM
Reply (8)

• !Report Abuse
View all 8 replies
u681694: Do you still think CYCC has long term potential as per your article ?
Mar 6, 3:06 PM
• !Report Abuse
StockMatusow: yes i do. but speculation wise. what if what goes down? what if a crazy man pisses on my lawn tomorrow?
Mar 6, 6:49 PM
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
Trade Alert: $CYCC Short Term Price Target Opion $6.10
12/3/12
Reply (23)

• !Report Abuse
View all 23 replies
amitschele: Well DANDISIK just when things start to look up we get another day in the trenches with ATRS.
12/13/12
• !Report Abuse
DANDISIK: @ amitschele $ATRS is becoming the ultimate either 1.) Tease Or 2.) Heartbreaker. Everyone needs to decide which one.
12/13/12
• !Report Abuse
Add a reply...

140 characters

The Scientist
CYCC came out with great data on sapacitabine for MDS. Not only does it work well, but it also an ORAL med. Wall St ignoring good data again
6/1/12
Reply (1)

• !Report Abuse
View all 1 replies
John Rayhall: Looks like they are listening today. Too late to buy some?
10/15/12
• !Report Abuse
Add a reply...

140 characters

The Scientist
CYCC recently trading at cash. Wall St saying their drugs are worth $0! Both lead drugs sapacitabine and seliciclib show activity.
5/21/12
Reply (1)

• !Report Abuse
View all 1 replies
The Scientist: Sapacitabine in P3 studies headed by chair of leukemia at MD Anderson. Valuation does not make sense.
5/21/12
• !Report Abuse
Add a reply...

140 characters

CYCC Cyclacel Pharmaceuticals, Inc.

CYCC

Cyclacel Pharmaceuticals, Inc.